Global Next Generation Antibody Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Next Generation Antibody Therapeutics Market Growth (Status and Outlook) 2023-2029

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

LPI (LP Information)' newest research report, the “Next Generation Antibody Therapeutics Industry Forecast” looks at past sales and reviews total world Next Generation Antibody Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Next Generation Antibody Therapeutics sales for 2023 through 2029. With Next Generation Antibody Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Next Generation Antibody Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Next Generation Antibody Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Next Generation Antibody Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Next Generation Antibody Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Next Generation Antibody Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Next Generation Antibody Therapeutics.

The global Next Generation Antibody Therapeutics market size is projected to grow from US$ 9392.2 million in 2022 to US$ 38470 million in 2029; it is expected to grow at a CAGR of 22.3% from 2023 to 2029.

Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of Next Generation Antibody Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)

Segmentation by application
Cancer
Haemophilia
Other Non-Cancer Diseases

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.